Lu et al. also suggested that anti-c-Met scFv (Ms20)-conjugated LD (Ms20-LD) can efficiently lead the liposomal drug to bind to c-Met receptor and induce an internalized mechanism and improve the IC50 to sixfold lower than unconjugated LD to lung cancer cells (H1993 and H441)29. Here, MET is linked to lung carcinoma.